Collegium Pharmaceutical, Inc (NASDAQ: COLL)

Collegium Pharmaceutical, Inc., often recognized by its stock symbol COLL, operates in the pharmaceutical industry with a focus on improving the lives of individuals with serious medical conditions through the development and commercialization of meaningfully differentiated products for the treatment of moderate to severe pain.

The company's primary business activities revolve around the development and commercialization of products for the treatment of moderate to severe pain, central nervous system disorders, and gastrointestinal issues. Collegium's operations span across various regions, primarily focusing on the United States healthcare market.

Collegium generates revenue through a diverse range of primary products and services. These include Xtampza ER, an extended-release, oral formulation of oxycodone with abuse-deterrent properties, indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Nucynta ER and Nucynta IR, tapentadol extended-release and immediate-release oral formulations, respectively, are also part of Collegium's offerings. Belbuca, a buccal film containing buprenorphine, is indicated for severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative options are inadequate. Symproic, a medication used to treat opioid-induced constipation in adult patients with chronic non-cancer pain, is another significant product in Collegium's portfolio.

Within the pharmaceutical industry, Collegium competes against various generic and branded drug companies, drug delivery companies, and academic and research institutions. Its primary source of competition originates from the generic opioid market, including both long-acting/extended-release and immediate-release opioid drugs. Despite facing intense competition, Collegium boasts a strong intellectual property portfolio, including patents and trade secrets. The company's issued patents are projected to expire in 2025, 2030, and 2036, while its pending patent applications, if issued, would be projected to expire in 2030 and 2036. Collegium also leverages trademarks and trade designs to develop and maintain its competitive position.

Collegium's products cater to patients with moderate to severe pain, including those who have not responded to other treatments or have developed tolerance to other opioids. The company's products are marketed and sold through a dedicated field sales force, consisting of approximately 110 sales representatives and managers, targeting the approximately 10,000 health care professionals who write approximately 66% of the branded extended-release opioid prescriptions in the United States.

Among the key brands and trade names of Collegium's products are Xtampza ER, Nucynta ER, Nucynta IR, Belbuca, and Symproic. These brands represent the company's commitment to providing innovative solutions for managing pain and gastrointestinal disorders.